Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 6;9(3):585–602. doi: 10.1002/jcsm.12289

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Alendronate (ALN) at a higher concentrations protected myotube from atrophy induced by dexamethasone (Dexa) in C2C12 myoblasts. C2C12 myoblasts were differentiated for 4 days under differentiation medium, followed by an additional 24 h with Dexa (1 μM) in the presence or absence of ALN (1, 5, and 10 μM). (A) The representative haematoxylin and eosin stained myotubes and the frequency distribution of myotube diameter were shown. (B) Western blot analysis of protein expressions of (a) Atrogin‐1, (b) SIRT3, and (c) SIRT1 in myotubes from C2C12 myoblasts was shown. All data are presented as means ± standard errors of the means for at least three independent experiments. The solid arrows indicated the multi‐nuclei myotubes. Scale bar = 100 μm. *P < 0.05 as compared with control group; #P < 0.05 as compared with Dexa group.